In cancer cells with defective homologous recombination repair (HRR) and double-stranded DNA repair, PARP inhibition can lead to synthetic lethality, a combinatorial effect caused by deficiencies in multiple pathways (10). The gene discussed is PARP1; the disease is cancer.